122 related articles for article (PubMed ID: 37061341)
1. Computational screening and structural analysis of Gly201Arg and Gly201Asp missense mutations in human cyclin-dependent kinase 4 protein.
Thirumal Kumar D; Shaikh N; Bithia R; Karthick V; George Priya Doss C; Magesh R
Adv Protein Chem Struct Biol; 2023; 135():57-96. PubMed ID: 37061341
[TBL] [Abstract][Full Text] [Related]
2. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity.
Lilischkis R; Sarcevic B; Kennedy C; Warlters A; Sutherland RL
Int J Cancer; 1996 Apr; 66(2):249-54. PubMed ID: 8603820
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation.
Bockstaele L; Bisteau X; Paternot S; Roger PP
Mol Cell Biol; 2009 Aug; 29(15):4188-200. PubMed ID: 19487459
[TBL] [Abstract][Full Text] [Related]
4. Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes.
Sarcevic B; Lilischkis R; Sutherland RL
J Biol Chem; 1997 Dec; 272(52):33327-37. PubMed ID: 9407125
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells.
Sweeney KJ; Sarcevic B; Sutherland RL; Musgrove EA
Oncogene; 1997 Mar; 14(11):1329-40. PubMed ID: 9178893
[TBL] [Abstract][Full Text] [Related]
6. Mutations associated with familial melanoma impair p16INK4 function.
Ranade K; Hussussian CJ; Sikorski RS; Varmus HE; Goldstein AM; Tucker MA; Serrano M; Hannon GJ; Beach D; Dracopoli NC
Nat Genet; 1995 May; 10(1):114-6. PubMed ID: 7647780
[TBL] [Abstract][Full Text] [Related]
7. Cyclins and CDKS in development and cancer: lessons from genetically modified mice.
Santamaria D; Ortega S
Front Biosci; 2006 Jan; 11():1164-88. PubMed ID: 16146805
[TBL] [Abstract][Full Text] [Related]
8. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors.
Parry D; Mahony D; Wills K; Lees E
Mol Cell Biol; 1999 Mar; 19(3):1775-83. PubMed ID: 10022865
[TBL] [Abstract][Full Text] [Related]
10. Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin-cdk complexes.
Jaumot M; Estanyol JM; Serratosa J; Agell N; Bachs O
Hepatology; 1999 Feb; 29(2):385-95. PubMed ID: 9918914
[TBL] [Abstract][Full Text] [Related]
11. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano M; Hannon GJ; Beach D
Nature; 1993 Dec; 366(6456):704-7. PubMed ID: 8259215
[TBL] [Abstract][Full Text] [Related]
12. Drosophila Cdk4 is required for normal growth and is dispensable for cell cycle progression.
Meyer CA; Jacobs HW; Datar SA; Du W; Edgar BA; Lehner CF
EMBO J; 2000 Sep; 19(17):4533-42. PubMed ID: 10970847
[TBL] [Abstract][Full Text] [Related]
13. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis.
Masaki T; Shiratori Y; Rengifo W; Igarashi K; Yamagata M; Kurokohchi K; Uchida N; Miyauchi Y; Yoshiji H; Watanabe S; Omata M; Kuriyama S
Hepatology; 2003 Mar; 37(3):534-43. PubMed ID: 12601350
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1).
Depoortere F; Pirson I; Bartek J; Dumont JE; Roger PP
Mol Biol Cell; 2000 Mar; 11(3):1061-76. PubMed ID: 10712520
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells.
Sandhu C; Garbe J; Bhattacharya N; Daksis J; Pan CH; Yaswen P; Koh J; Slingerland JM; Stampfer MR
Mol Cell Biol; 1997 May; 17(5):2458-67. PubMed ID: 9111314
[TBL] [Abstract][Full Text] [Related]
16. Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.
Cammett TJ; Luo L; Peng ZY
J Mol Biol; 2003 Mar; 327(1):285-97. PubMed ID: 12614625
[TBL] [Abstract][Full Text] [Related]
17. B cell antigen receptor-mediated activation of cyclin-dependent retinoblastoma protein kinases and inhibition by co-cross-linking with Fc gamma receptors.
Tanguay D; Pavlovic S; Piatelli MJ; Bartek J; Chiles TC
J Immunol; 1999 Sep; 163(6):3160-8. PubMed ID: 10477583
[TBL] [Abstract][Full Text] [Related]
18. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points.
Mateyak MK; Obaya AJ; Sedivy JM
Mol Cell Biol; 1999 Jul; 19(7):4672-83. PubMed ID: 10373516
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle protein suppression and p21 induction in differentiating Caco-2 cells.
Evers BM; Ko TC; Li J; Thompson EA
Am J Physiol; 1996 Oct; 271(4 Pt 1):G722-7. PubMed ID: 8897894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
